SRR934788
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 129.23784494086726
- age_years
- 45
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.456
- ANDROGEN_RESPONSE+0.424
- MITOTIC_SPINDLE+0.373
- E2F_TARGETS+0.370
- G2M_CHECKPOINT+0.366
- TGF_BETA_SIGNALING+0.347
- UV_RESPONSE_DN+0.343
- HEDGEHOG_SIGNALING+0.305
- MTORC1_SIGNALING+0.301
- UNFOLDED_PROTEIN_RESPONSE+0.299
Top 10 suppressed
- KRAS_SIGNALING_DN-0.333
- MYOGENESIS-0.276
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.259
- COAGULATION-0.248
- APICAL_SURFACE-0.234
- ALLOGRAFT_REJECTION-0.173
- SPERMATOGENESIS-0.172
- APICAL_JUNCTION-0.155
- INFLAMMATORY_RESPONSE-0.058
- IL6_JAK_STAT3_SIGNALING-0.043
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934795 | — | — | 0.867 |
| 2 | SRR934819 | — | — | 0.857 |
| 3 | 8EFB3C39-094A-4F91-8B8D-EE8A32AC7E1F | — | — | 0.854 |
| 4 | SRR934799 | — | — | 0.850 |
| 5 | 7CE18C10-61E6-45FA-B9AF-408CD673C0C9 | — | — | 0.847 |
| 6 | SRR934826 | — | — | 0.844 |
| 7 | 07D10802-F79E-495E-B842-895C444CA439 | — | — | 0.835 |
| 8 | SRR934756 | — | — | 0.835 |
| 9 | MDT-AP-3249 | Med | Medulloblastoma | 0.834 |
| 10 | 27F3611B-6483-47F5-A58E-A74B5165514A | — | — | 0.833 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.456 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.424 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.373 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.370 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.366 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.347 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.343 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.305 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.301 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.299 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.283 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.236 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.225 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.219 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.185 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.154 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.152 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.147 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.119 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.103 | Inavolisib | — uncovered |